Omaha, NE, United States
Omaha, NE, United States
SEARCH FILTERS
Time filter
Source Type

Global Pharmacogenomics Market Information by Application (drug safety, Tailor treatments, drug discovery), By Therapeutic application (cancer, oncology, cardiovascular) By Methods (haplotype analysis, multivariate techniques) - Forecast to 2027Pune, India - April 25, 2017 /MarketersMedia/ — Market Highlights: Pharmacogenomics are popularly known as personalized medicines and are defined as Customized/ personalized medicines or customized medical treatment to the specific characteristics of each patient. This notion basically, comprises the ability to classify individuals into the groups or categories that are uniquely or excessively prone to a particular disease or responsive to a specific treatment. Emergence of new healthcare technologies and rapid advancement such as GenX sequencing, Digital Polymerase Chain Reaction (PCR) and High Throughput Screening (HTS), are the key driving factors for the global market of Pharmacogenomics. With the increasing demand for diagnostic tests leaded by the growing emphasize of patients on pre-diagnosis treatments, increasing genetic disorders & mutational diseases, and government initiatives and investment in research and development programs, the Diagnostic Test segment has out grown the other segments holding the largest market share. Key Players • Myriad Genetics, Inc (U.S) • Transgenomic, Inc(U.S) • 23andMe (U.S) • Pathway Genomics (CA) • Genetech (CA) • GeneDX (U.S) • Teva Pharmaceutical Industries Ltd.(Israel) • Illumina, Inc.(U.s) • Assurex Health, Inc.(U.s) Request a Copy of Sample Report @ https://www.marketresearchfuture.com/sample_request/1177 Global Pharmacogenomics Market’s Current trends are prompting the service provider segments to collaborate and entering into partnerships with healthcare providers, academic institutions, pharmaceuticals and biotechnology companies to support the growth of the Pharmacogenomics market and thus, service segment is anticipated to grow at a high CAGR from 2016 to 2027 Furthermore, the Pharmaceutical segment will also gain from traction of the patients due to increasing awareness about the benefits of Pharmacogenomics solutions and adoption of these solutions in developing regions. The report for Pharmacogenomics of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. Segments The market for pharmacogenomics is segmented into mainly three; by application, by therapeutic application, by end user and its various sub-segments. By application include drug safety, Tailor treatments, drug discovery and others. Whereas by therapeutic application include cancer, oncology, cardiovascular and others. Furthermore by methods include haplotype analysis, multivariate techniques, quantitative trait analysis and others. Taste the market data and market information presented through more than 50 market data tables and figures spread in 120 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Pharmacogenomics Market Research Report - Forecast to 2027” Access Report Details @ https://www.marketresearchfuture.com/reports/pharmacogenomics-market Study Objectives of Pharmacogenomics • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the global pharmacogenomics market • To provide insights about factors affecting the market growth • To Analyze the Pharmacogenomics Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia, and Middle East & Africa. • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segment by application, by therapeutic application, by methods and its sub-segments. • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global pharmacogenomics market. Make an Enquiry @ https://www.marketresearchfuture.com/enquiry/1177 Americas • North America • US • Canada • Latin America Europe • Western Europe • Germany • France • Italy • Spain • UK • Rest of Western Europe • Eastern Europe Asia– Pacific Asia • China • India • Japan • South Korea • Rest of Asia Pacific The Middle East& Africa The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions. Browse Related Reports:- Global Infusion Systems market, by Product Type (Ambulatory Pumps, I.V. Disposables, Syringe Pump Systems, Volumetric Pump Sets and others), by applications (chemotherapy, cardiovascular diseases, Diabetes, Pediatrics and others) by end users (Hospitals, Clinics, Research Laboratories and others) - Forecast to 2027 https://www.marketresearchfuture.com/reports/infusion-systems-market About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. Contact Info:Name: Akash AnandEmail: akash.anand@marketresearchfuture.comOrganization: Market Research FutureAddress: Hadapsar Pune, India - 411028Phone: +1 646 845 9312Source URL: http://marketersmedia.com/pharmacogenomics-market-analysis-by-global-industry-growth-regions-types-and-forecasts-2027/190043For more information, please visit https://www.marketresearchfuture.com/reports/pharmacogenomics-marketSource: MarketersMediaRelease ID: 190043


News Article | April 17, 2017
Site: www.businesswire.com

OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCQB:TBIO) today reported that it has received $1.15 million in proceeds from a note bridge financing. The financing is intended to help facilitate the completion of Transgenomic’s merger with Precipio Diagnostics, LLC, which is expected to close during the second quarter of 2017. As part of the financing, Transgenomic agreed to loan 50% of the net proceeds from the sale of the bridge notes to Precipio upon substantially the same terms and conditions as the bridge notes. Transgenomic may receive additional investments of up to $100,000 in connection with the financing. Aegis Capital Corp. acted as placement agent for the note bridge financing. Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in oncology and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR, which enables use of liquid biopsies for mutation detection. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes. Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets, expectations regarding new clients, projects and prospects, and MX-ICP’s ability to accelerate the Company’s growth and generate revenue. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission (SEC). Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law. In connection with the proposed merger, Transgenomic has filed with the SEC a preliminary proxy statement relating to the approval of the merger agreement. The information in the preliminary proxy statement is not complete and may be changed. The preliminary proxy statement and this press release are not offers to sell Transgenomic securities and are not soliciting an offer to buy Transgenomic securities in any state where the offer and sale is not permitted. The definitive proxy statement will be mailed to stockholders of Transgenomic. TRANSGENOMIC URGES INVESTORS AND SECURITY HOLDERS TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the definitive proxy statement (when available) and other documents filed with the SEC by Transgenomic through the web site maintained by the SEC at www.sec.gov. Free copies of the definitive proxy statement (when available) and other documents filed with the SEC can also be obtained on Transgenomic’s website at www.transgenomic.com/ir/investor-information. Transgenomic and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Transgenomic in connection with the merger. Information about the directors and executive officers of Transgenomic is set forth in Transgenomic’s annual report on Form 10-K filed with the SEC on April 13, 2017. Additional information regarding the interests of these participants and other persons who may be deemed participants in the merger may be obtained by reading the definitive proxy statement regarding the proposed transaction when it becomes available.


OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCQB: TBIO), today announced that its Board of Directors confirms its special meeting of stockholders will be held on June 5, 2017 at Troutman Sanders LLP’s offices located at 1001 Haxall Point, Richmond, Virginia 23219. The purpose of this meeting is to vote on the proposed merger with Precipio Diagnostics and certain other matters. All stockholders of record as of April 12, 2017 are eligible to vote at this meeting, or prior to the meeting by mail or by electronic submission of their vote. A Proxy Statement and all materials related to the transaction have been mailed to stockholders, and the Board of Directors recommends a vote in favor of all proposals. If you owned stock of Transgenomic on April 12, 2017, but have not received proxy materials, please contact Innisfree M&A Incorporated at (888) 750-5834 immediately to have them sent. “ This reverse split is a necessary step that will satisfy one of the key requirements for the stock to be relisted on NASDAQ,” said Ilan Danieli, CEO of Precipio. “ The Board will be joined by new experienced directors who, alongside an experienced management team assembled from both companies, will embark on a new vision that has been derived from the combination of both companies, which we will be sharing publicly immediately post-merger.” In conjunction with the proposed merger, and as part of the Company’s plan to re-list its common shares on NASDAQ, Transgenomic’s Board of Directors has approved a 1-for-30 reverse split of its issued and outstanding shares of common stock. The planned effective date of the reverse split is 5:00 p.m. EDT on June 5, 2017. After the reverse split, the number of shares outstanding will be reduced from approximately 26.8 million shares to approximately 0.9 million shares. The number of outstanding shares of common stock after the reverse split does not take into account the shares of Company common stock and preferred stock to be issued in connection with the merger with Precipio Diagnostics, and the related transactions, including the conversion of certain secured indebtedness of the Company and a proposed private placement of preferred stock by the Company to certain investors. The merger and the transactions relating to the merger are expected to close in June 2017. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares following the reverse split. Holders of share certificates will receive instructions from the Company’s transfer agent, Wells Fargo Bank Minnesota, N.A., regarding the process for exchanging their shares. Wells Fargo Bank Minnesota, N.A. can be reached at (800) 468-9716. Additional Information for Transgenomic Common Stockholders In connection with the proposed merger, Transgenomic has filed with the Securities and Exchange Commission (“SEC”) a definitive proxy statement relating to the approval of the merger agreement. The definitive proxy statement and this press release are not offers to sell Transgenomic securities and are not soliciting an offer to buy Transgenomic securities in any state where the offer and sale is not permitted. The definitive proxy statement was mailed to stockholders of Transgenomic on May 15, 2017. TRANSGENOMIC URGES INVESTORS AND SECURITY HOLDERS TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of the definitive proxy statement and other documents filed with the SEC by Transgenomic through the website maintained by the SEC at www.sec.gov. Free copies of the definitive proxy statement and other documents filed with the SEC can also be obtained on Transgenomic’s website at www.transgenomic.com/ir/investor-information. Transgenomic, Precipio Diagnostics, LLC and each of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Transgenomic in connection with the merger. Information about the directors and executive officers of Transgenomic is set forth in Transgenomic’s proxy statement filed with the SEC on April 29, 2016 in connection with its annual meeting, and in Transgenomic’s definitive proxy statement filed with the SEC on May 12, 2017 in connection with the proposed merger. Additional information regarding the interests of these participants and other persons who may be deemed participants in the merger may be obtained by reading the definitive proxy statement regarding the proposed transaction. Forward-Looking Statements Certain statements in this press release constitute “forward-looking statements” of Transgenomic, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of Transgenomic to grow its involvement in the diagnostic products and services markets, expectations regarding new clients, projects and prospects, and MX-ICP’s ability to accelerate Transgenomic’s growth and generate revenue. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the SEC. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law. About Transgenomic, Inc. Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in oncology and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR, which enables use of liquid biopsies for mutation detection. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes. About Precipio Diagnostics Precipio Diagnostics has built a platform to harness the intellect, expertise and technology developed within academia, delivering quality diagnostic information to physicians and patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, and its experience delivering quality service, Precipio Diagnostics offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, visit www.precipiodx.com.


Grant
Agency: Department of Health and Human Services | Branch: | Program: STTR | Phase: Phase I | Award Amount: 200.00K | Year: 2013

DESCRIPTION (provided by applicant): Cancers develop from the life-long accumulation of critical somatic mutations due to DNA-damaging agents that lead to cells transforming into tumor-forming cells. These low-level tumor-associated somatic DNA mutations can have profound implications for development of metastasis, prognosis, choice of treatment, follow-up or early cancer detection. Unless they are effectively detected, these low-level mutations can misinform patient management decisions or become missed opportunities for personalized medicine. Widely-used technologies such as sequencing are not sensitive enough to detect these mutations when they are at very low percentages compared to normal DNA. Likewise the next generation sequencing technologies (NGS)are promising technology advances that can effectively detect prevalent somatic mutations in targeted gene panels; however due to the limited quantity of DNA in most patient samples and the abundance of normal DNA when analyzing blood, NGS 'loses steam' and its integration with clinical practice is problematic. For mutations at an abundance of ~2-5% or below, NGS generates false positives ('noise') independent of sequencing depth; yet these are often the clinically relevant mutations causing resistance todrug treatments. Commercial sample preparation kits for targeted re-sequencing of cancer gene panels have emerged1-3, however they are uniformly unable to detect mutations below a 2% abundance level. Thus, while targeted re-sequencing provides an opportunity for integration of NGS with clinical oncology, the technology is ineffective in detecting DNA mutations in heterogeneous cancers or in circulating DNA. We intend to use COLD-PCR, a new method that enriches unknown mutation-containing sequences over wild-type, normal alleles during PCR amplification. We have been able to show sequencing of mutations down to 0.02% abundance. However in its current form this method only can be used with single amplicon per reaction, limiting its efficient combination withNGS. In this project we propose a simple and powerful modification that enables COLD-PCR to be applied on hundreds or thousands of DNA targets in a single reaction, thus enabling mutation enrichment in cancer- specific gene panels prior to NGS. This wouldconvert the rare mutations to high abundance mutations, overcoming the 'noise' and avoid the costly need for repeated sequence reads during NGS. This method, known as temperature-tolerant-COLD-PCR (TT-COLD-PCR), will be developed into kits for cancer-specific gene panels, to magnify rare mutations in multiple DNA targets thus enabling expanded application of targeted re-sequencing for heterogeneous cancers or circulating DNA. This project meets one of the stated aims of the NCI to support the developmentof new methods of diagnosis for the detection, discovery and validation of biomarkers for cancer detection, diagnosis and prognosis. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The selection of the best available cancer treatment is, in many instances, dependent on the genetic profile of the patient's cancer cells. This can be difficult to determine when there is limited availability of tumor DNA, as when analyzing blood, when obscured by far more abundant healthy cell DNA and when many DNAtargets need to be analyzed. This project aims to develop a multiplexed DNA analysis technique that enriches low abundance cancer mutations in clinical specimens such as blood to improve cancer treatment selection.


Grant
Agency: Department of Health and Human Services | Branch: | Program: STTR | Phase: Phase I | Award Amount: 100.00K | Year: 2012

DESCRIPTION (provided by applicant): Ninety percent of all pancreatic cancers are pancreatic ductal adenocarcinoma (PDAC). PDAC diagnosis is difficult, usually occurring in the late stages of disease. Patients with these advanced tumors typically respondpoorly to therapy. Post diagnosis, median survival is 6 months and the five-year survival rate is lt 4%. Five-year survival is lt 1% for those with advanced cancer. Progression to advanced disease occurs with few, if any, symptoms but studies have shown that there is a long period of time during which early detection may be possible. There appears to be a timeline for detection of specific biomarkers during the disease's development: (1) in Stage 1a, mutations in K-RAS occur early when there are minimal visible cytological, morphological or symptomatic changes; (2) in Stages1b and 2, additional genetic mutations occur that lead to Her-2 overexpression and p16 inactivation; (3) in Stage 3, mutations occur in the TP53, DPC4, and BRCA2 genes. The lack of symptoms in the early stages means that patients go undetected until the later stages when treatments may not be as effective. It is not feasible to routinely test pancreatic tissues for markers of early disease and it has been difficult to identify disease markers in plasma, serum and/or urine that might enable early disease detection. The discovery of the accumulated mutations in many human pancreatic tumors, specifically in K-RAS and TP53, has suggested that pancreatic cancer animal models are useful for the study of disease development. These mouse models will be used to test the application of Ice COLD-PCR to the high sensitive detection of K- RAS and Trp53 mutations in urine and blood. Further, this model system will allow the study of pancreatitis- relatedprogression to pancreatic cancer stage 1 in a mutant K-RAS background. Pancreatitis will be induced in these mice models which will enable a time-line investigation of early detection of K-RAS and Trp53 mutations in murine samples. The method will be further validated in several tissues from well-characterized human pancreatic autopsy samples, including pancreas, blood and urine. If promising results are obtained from these Phase I studies, a Phase II STTR application will include more comprehensive studiesof Ice COLD-PCR detection of DNA mutations associated with early and late stage pancreatic cancer in humans. This could ultimately lead to a simple, highly sensitive diagnostic assay for the early detection of pancreatic ductal adenocarcinoma. PUBLIC HEALTH RELEVANCE: Pancreatic cancer is difficult to diagnose at an early stage. In the disease's late stage response to therapy is poor with an average survival of 6 months after diagnosis and a five-year survival rate of less than 4%. We aim to develop a highly sensitive genetic test that can detect pancreatic cancer biomarkers in blood or urine, enabling much earlier diagnosis and more effective treatment.


The present invention relates to a polymorphic MRP-1 polynucleotide, genes or vectors comprising the polynucleotides and a host cell genetically engineered with the polynucleotide or gene. Also provided are methods for producing molecular variant polypeptides, cells capable of expressing a molecular variant polypeptide and a polypeptide encoded by the polynucleotide or the gene or obtainable by the method or cells produced herein. Also provided is an antibody to the polypeptide, a transgenic animal, and a solid support comprising one or a plurality of the provided polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also provided. In addition, the invention relates to methods for producing a pharmaceutical composition, diagnosing a disease and detection of the polynucleotide. Furthermore, provided herein are uses of the polynucleotides, genes, vectors, polypeptides or antibodies herein.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: STTR | Phase: Phase II | Award Amount: 773.51K | Year: 2016

DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used technologies such as sequencing are not sensitive enough to detect these mutations when they are at very low percentages compared to normal DNA Likewise the next generation sequencing technologies NGS are promising technology advances that can effectively detect prevalent somatic mutations in targeted gene panels however due to the limited quantity of DNA in most patient samples and the abundance of normal DNA when analyzing blood NGS andapos loses steamandapos and its integration with clinical practice is problematic For mutations at an abundance of or below NGS generates false positives `noiseandapos independent of sequencing depth yet these are often the clinically relevant mutations causing resistance to drug treatments Commercial sample preparation kits for targeted re sequencing of cancer gene panels have emerged however they are uniformly unable to detect mutations below a abundance level Thus while targeted re sequencing provides an opportunity for integration of NGS with clinical oncology the technology is ineffective in detecting DNA mutations in circulating DNA urine or heterogeneous cancers We intend to use COLD PCR a recently developed method that enriches unknown mutation containing sequences over wild type normal alleles during PCR amplification In previous work we showed COLD PCR NGS based sequencing for mutations down to abundance However COLD PCR was only applicable with a single amplicon per reaction limiting its efficient combination with NGS This STTR proposes a simple and powerful modification that enables COLD PCR to be applied to hundreds or thousands of DNA targets in a single reaction thus enabling mutation enrichment in disease specific gene panels prior to NGS The new approach temperature tolerant COLD PCR TT COLD PCR converts the rare mutations to high abundance mutations overcoming the `noiseandapos and avoiding the costly need for repeated sequence reads during NGS In Phase I we obtained proof of principle for TT COLD PCR In Phase II TT COLD PCR will be developed into kits for cancer specific gene panels to magnify rare mutations in multiple DNA targets thus enabling expanded application of targeted re sequencing for heterogeneous cancers or circulating DNA This project meets one of the aims of the NCI to support the development of new methods of diagnosis for the detection discovery and validation of biomarkers for cancer detection diagnosis and prognosis PUBLIC HEALTH RELEVANCE Screening of patientsandapos tumors for genetic alterations over many genes in a minimally invasive rapid and cost effective manner is a significant challenge that must be fulfilled in order to realize the promise of individualized cancer treatment Although major advances have been made there is still a significant gap in technology that prevents molecular profiling from repeated blood collections `liquid biopsiesandapos This STTR project provides an answer to this challenge by employing a new technology TT COLD PCR in combination with Next Generation Sequencing This novel approach overcomes technical limitations and enables reliable mutation screening in multiple genes simultaneously in bodily fluids or surgical cancer samples from individual patients In view of the fundamental role of mutations in causing cancer and modulating tumor response to drug treatment this project has significant implications for public health


Patent
Transgenomic, Inc. | Date: 2014-01-10

The invention is based, at least in part, on the observation that the presence of particular biomarkers, e.g., particular mutations in any of the KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2 genes as identified in Tables 1-5 (and, in particular, those identified with an asterisk), is associated with Long QT Syndrome (LQTS).


Patent
Transgenomic, Inc. | Date: 2013-03-15

Methods of using polymerase chain reactions to enrich a target sequence in a sample containing reference sequences and target sequences having high homology and amplifiable by the same primer pair are provided herein. In particular the methods provide a robust means to improve the fold enrichment of the target sequence and minimize reaction-to-reaction, well-to-well and run-to-run variations in the enrichment methods.


Patent
Transgenomic, Inc. | Date: 2012-02-28

Methods and kits for sequencing a target DNA sequence in a sample having a related reference sequence are provided herein. In particular, kits and methods for sequencing cancer and cancer therapy associated mutations are described. Also provided are kits and methods for detecting mitochondrial mutations and for differentiating between closely related viral strains.

Loading Transgenomic, Inc. collaborators
Loading Transgenomic, Inc. collaborators